Nivolumab as Second-Line Therapy Improves Survival in Patients with Unresectable Hepatocellular Carcinoma.

Cancers (Basel) · 2024 · PMC11202187 · PMID 38927902

Europe PMC DOI

hedged sentences

0.0680

closest p · 1.4× alpha

0.1500

boldest claim

The sentences

showed a trendp = 0.068so close (0.05 < p ≤ 0.1)

CTP A patients in the nivolumab arm showed a trend to longer mOS, with 31.2 months (95% CI: 12.6–72.8) compared to 14.2 months (95% CI: 1.9–26.5) in the sorafenib only arm (HR 1.80; 95% CI: 0.95–3.44, p = 0.068; Figure 2 A).

also in 53,322 other papers

did not reach statistical significancep = 0.15not close (p > 0.1)

21.1%), although this did not reach statistical significance ( p = 0.15; Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.